Table of Contents Author Guidelines Submit a Manuscript
Current Gerontology and Geriatrics Research
Volume 2010, Article ID 915296, 9 pages
http://dx.doi.org/10.1155/2010/915296
Review Article

Use of Statin Therapy to Reduce Cardiovascular Risk in Older Patients

1Grady Memorial Hospital, School of Medicine, Emory University, Atlanta, GA 30303, USA
2Department of Medicine, Northwest Cardiovascular Institute, Portland, OR 97210, USA

Received 30 October 2009; Accepted 30 March 2010

Academic Editor: Thomas M. Stulnig

Copyright © 2010 N. K. Wenger and S. J. Lewis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Lloyd-Jones, R. Adams, M. Carnethon et al., “Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 119, no. 3, pp. e21–e181, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. H. C. Kung, D. L. Hoyert, J. Xu, and S. L. Murphy, “Deaths: final data for 2005,” National Vital Statistics Reports, vol. 56, no. 10, pp. 1–120, 2008. View at Google Scholar · View at Scopus
  3. “Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report,” Circulation, vol. 106, no. 25, pp. 3143–3421, 2002. View at Scopus
  4. S. M. Grundy, J. I. Cleeman, C. N. Merz et al., “Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines,” Circulation, vol. 110, no. 2, pp. 227–239, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. J. L. Anderson, C. D. Adams, E. M. Antman et al., “ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,” Journal of the American College of Cardiology, vol. 50, pp. e1–e157, 2007. View at Google Scholar
  6. T. D. Fraker Jr. and S. D. Fihn, “2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina. A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines writing group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina,” Journal of the American College of Cardiology, vol. 50, no. 23, pp. 2264–2274, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Y. Pan, A. P. Waclawski, P. T. Funke, and D. Whigan, “Pharmacokinetics of pravastatin in elderly versus young men and women,” Annals of Pharmacotherapy, vol. 27, no. 9, pp. 1029–1033, 1993. View at Google Scholar · View at Scopus
  8. D. M. Gibson, N. J. Bron, A. Richens, N. J. Hounslow, A. J. Sedman, and L. R. Whitfield, “Effect of age and gender on pharmacokinetics of atorvastatin in humans,” Journal of Clinical Pharmacology, vol. 36, no. 3, pp. 242–246, 1996. View at Google Scholar · View at Scopus
  9. P. D. Martin, A. L. Dane, O. M. Nwose, D. W. Schneck, and M. J. Warwick, “No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor,” Journal of Clinical Pharmacology, vol. 42, no. 10, pp. 1116–1121, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. T. R. Pedersen, “Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S),” Lancet, vol. 344, no. 8934, pp. 1383–1389, 1994. View at Google Scholar · View at Scopus
  11. F. M. Sacks, M. A. Pfeffer, L. A. Moye et al., “The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels,” The New England Journal of Medicine, vol. 335, no. 14, pp. 1001–1009, 1996. View at Publisher · View at Google Scholar · View at Scopus
  12. “Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group,” The New England Journal of Medicine, vol. 339, pp. 1349–1357, 1998.
  13. S. J. Lewis, L. A. Moye, F. M. Sacks et al., “Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial,” Annals of Internal Medicine, vol. 129, no. 9, pp. 681–689, 1998. View at Google Scholar · View at Scopus
  14. D. Hunt, P. Young, J. Simes et al., “Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial,” Annals of Internal Medicine, vol. 134, no. 10, pp. 931–940, 2001. View at Google Scholar · View at Scopus
  15. T. A. Miettinen, K. Pyorala, A. G. Olsson et al., “Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S),” Circulation, vol. 96, no. 12, pp. 4211–4218, 1997. View at Google Scholar · View at Scopus
  16. R. N. Lemaitre, B. M. Psaty, S. R. Heckbert, R. A. Kronmal, A. B. Newman, and G. L. Burke, “Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the cardiovascular health study,” Archives of Internal Medicine, vol. 162, no. 12, pp. 1395–1400, 2002. View at Google Scholar · View at Scopus
  17. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto, “MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial,” Lancet, vol. 360, no. 9326, pp. 7–22, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. P. S. Sever, B. Dahlof, N. R. Poulter et al., “Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial,” Lancet, vol. 361, no. 9364, pp. 1149–1158, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. J. Shepherd, G. J. Blauw, M. B. Murphy et al., “Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial,” Lancet, vol. 360, no. 9346, pp. 1623–1630, 2002. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J. M. de Craen, and M. J. Eisenberg, “Statins for secondary prevention in elderly patients. A hierarchical Bayesian meta-analysis,” Journal of the American College of Cardiology, vol. 51, no. 1, pp. 37–45, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. J. Brugts, T. Yetgin, S. E. Hoeks et al., “The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials,” British Medical Journal, vol. 338, p. b2376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. K. Wenger, S. J. Lewis, D. M. Herrington, V. Bittner, and F. K. Welty, “Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease,” Annals of Internal Medicine, vol. 147, no. 1, pp. 1–9, 2007. View at Google Scholar · View at Scopus
  23. M. J. Koren, T. Feldman, and R. A. Mendes, “Impact of high-dose atorvastatin in coronary heart disease patients age 65 to 78 years,” Clinical Cardiology, vol. 32, no. 5, pp. 256–263, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. P. Deedwania, P. H. Stone, C. N. B. Merz et al., “Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE),” Circulation, vol. 115, no. 6, pp. 700–707, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. W. Massing, C. A. Sueta, M. Chowdhury, D. P. Biggs, and R. J. Simpson, “Lipid management among coronary artery disease patients with diabetes mellitus or advanced age,” American Journal of Cardiology, vol. 87, no. 5, pp. 646–649, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. G. A. Nichols, S. Nag, and W. Chan, “Intensity of lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment among the elderly before and after the 2004 National Cholesterol Education Program Adult Treatment Panel III update,” American Heart Journal, vol. 154, pp. 554–560, 2007. View at Google Scholar
  27. S. M. Grundy, R. Pasternak, P. Greenland, S. Smith, and V. Fuster, “Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology,” Journal of the American College of Cardiology, vol. 34, no. 4, pp. 1348–1359, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Junyent, D. Zambon, R. Gilabert et al., “Carotid atherosclerosis and vascular age in the assessment of coronary heart disease risk beyond the Framingham Risk Score,” Atherosclerosis, vol. 196, no. 2, pp. 803–809, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. W. B. Kannel and R. B. D'Agostino, “The importance of cardiovascular risk factors in the elderly,” American Journal of Geriatric Cardiology, vol. 4, no. 2, pp. 10–23, 1995. View at Google Scholar · View at Scopus
  30. J. A. de Lemos, M. A. Blazing, S. D. Wiviott et al., “Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial,” Journal of the American Medical Association, vol. 292, no. 11, pp. 1307–1316, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. E. Link, S. Parish, J. Armitage et al., “SLCO1B1 variants and statin-induced myopathy—a genomewide study,” The New England Journal of Medicine, vol. 359, no. 8, pp. 789–799, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. K. P. Alexander, M. A. Blazing, R. S. Rosenson et al., “Management of hyperlipidemia in older adults,” Journal of Cardiovascular Pharmacology and Therapeutics, vol. 14, no. 1, pp. 49–58, 2009. View at Publisher · View at Google Scholar · View at PubMed
  33. C. P. Cannon, E. Braunwald, C. H. McCabe et al., “Intensive versus moderate lipid lowering with statins after acute coronary syndromes,” The New England Journal of Medicine, vol. 350, no. 15, pp. 1495–1504, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. G. G. Schwartz, A. G. Olsson, M. D. Ezekowitz et al., “Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial,” Journal of the American Medical Association, vol. 285, no. 13, pp. 1711–1718, 2001. View at Google Scholar
  35. K. K. Ray, R. G. Bach, C. P. Cannon et al., “Benefits of achieving the NCEP optional LDL-C goal among elderly patients with ACS,” European Heart Journal, vol. 27, no. 19, pp. 2310–2316, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. A. G. Olsson, G. G. Schwartz, M. Szarek, D. Luo, and M. J. Jamieson, “Effects of high-dose atorvastatin in patients 65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study),” American Journal of Cardiology, vol. 99, no. 5, pp. 632–635, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. N. K. Wenger, J. LaRosa, J. Shepherd et al., “High-dose atorvastatin provides sustained benefit in reducing risk of cardiovascular disease among stable coronary heart disease patients 65 years of age or older,” in Proceedings of the American College of Cardiology 58th Annual Scientific Session, Orlando, Fla, USA, 2009.
  38. K. G. Alberti, P. Zimmet, and J. Shaw, “Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation,” Diabetic Medicine, vol. 23, no. 5, pp. 469–480, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. J. Shepherd, P. Barter, R. Carmena et al., “Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the treating to new targets (TNT) study,” Diabetes Care, vol. 29, no. 6, pp. 1220–1226, 2006. View at Publisher · View at Google Scholar · View at PubMed
  40. J. Shepherd, J. J. Kastelein, V. Bittner et al., “Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease. The TNT (Treating to New Targets) study,” Journal of the American College of Cardiology, vol. 51, no. 15, pp. 1448–1454, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. J. Shepherd, J. J. Kastelein, V. A. Bittner et al., “Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease,” Mayo Clinic Proceedings, vol. 83, no. 8, pp. 870–879, 2008. View at Publisher · View at Google Scholar
  42. P. M. Ridker, E. Danielson, F. A. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at PubMed
  43. B. Dahlof, P. S. Sever, N. R. Poulter et al., “Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial,” Lancet, vol. 366, no. 9489, pp. 895–906, 2005. View at Publisher · View at Google Scholar · View at PubMed
  44. D. J. Collier, N. R. Poulter, B. Dalhof et al., “Impact of atorvastatin on cardiovascular events in 2440 men and women aged 65 years and above: evidence from the Anglo-Scandinavian outcomes Trial-Lipid Lowering Arm (ASCOT-LLA),” Stroke, vol. 37, p. 692, 2006. View at Google Scholar
  45. J. C. LaRosa, S. M. Grundy, D. D. Waters et al., “Intensive lipid lowering with atorvastatin in patients with stable coronary disease,” The New England Journal of Medicine, vol. 352, no. 14, pp. 1425–1435, 2005. View at Publisher · View at Google Scholar · View at PubMed
  46. M. J. Tikkanen, I. Holme, N. B. Cater et al., “Comparison of efficacy and safety of atorvastatin (80 mg) to simvastatin (20 to 40 mg) in patients aged <65 Versus 65 years with coronary heart disease (from the incremental decrease through aggressive lipid lowering [IDEAL] study),” American Journal of Cardiology, vol. 103, no. 5, pp. 577–582, 2009. View at Publisher · View at Google Scholar · View at PubMed
  47. J. H. Hey-Hadavi, E. Kuntze, D. Luo, P. Silverman, D. Pittman, and B. LePetri, “Tolerability of atorvastatin in a population aged 65 years: a retrospective pooled analysis of results from fifty randomized clinical trials,” American Journal of Geriatric Pharmacotherapy, vol. 4, no. 2, pp. 112–122, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. J. Hey-Hadavi, R. Laskey, and A. Breazna, “Atorvastatin safety in patients 75 years and older,” in Proceedings of the 16th International Symposium on Drugs Affecting Lipid Metabolism, New York, NY, USA, 2007.
  49. A. A. Alsheikh-Ali and R. H. Karas, “Adverse events with concomitant amiodarone and statin therapy,” Preventive Cardiology, vol. 8, no. 2, pp. 95–97, 2005. View at Google Scholar
  50. P. J. Neuvonen, M. Niemi, and J. T. Backman, “Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance,” Clinical Pharmacology and Therapeutics, vol. 80, no. 6, pp. 565–581, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. M. H. Davidson and J. G. Robinson, “Safety of aggressive lipid management,” Journal of the American College of Cardiology, vol. 49, no. 17, pp. 1753–1762, 2007. View at Publisher · View at Google Scholar · View at PubMed
  52. T. Westergren, P. Johansson, and E. Molden, “Probable warfarin-simvastatin interaction,” Annals of Pharmacotherapy, vol. 41, no. 7-8, pp. 1292–1295, 2007. View at Publisher · View at Google Scholar · View at PubMed
  53. R. Stern, R. Abel, G. L. Gibson, and J. Besserer, “Atorvastatin does not alter the anticoagulant activity of warfarin,” Journal of Clinical Pharmacology, vol. 37, no. 11, pp. 1062–1064, 1997. View at Google Scholar
  54. M. H. Davidson, A. Armani, J. M. McKenney, and T. A. Jacobson, “Safety considerations with fibrate therapy,” American Journal of Cardiology, vol. 99, no. 6, pp. 3C–18C, 2007. View at Publisher · View at Google Scholar · View at PubMed
  55. G. C. Kane and J. J. Lipsky, “Drug-grapefruit juice interactions,” Mayo Clinic Proceedings, vol. 75, no. 9, pp. 933–942, 2000. View at Google Scholar
  56. K. Sugimoto, M. Ohmori, S. Tsuruoka et al., “Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin,” Clinical Pharmacology and Therapeutics, vol. 70, no. 6, pp. 518–524, 2001. View at Publisher · View at Google Scholar
  57. J. M. Foody, A. T. Joyce, A. E. Rudolph, L. Z. Liu, and J. S. Benner, “Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study,” Current Medical Research and Opinion, vol. 24, no. 7, pp. 1987–2000, 2008. View at Publisher · View at Google Scholar · View at PubMed
  58. J. S. Benner, R. J. Glynn, H. Mogun, P. J. Neumann, M. C. Weinstein, and J. Avorn, “Long-term persistence in use of statin therapy in elderly patients,” Journal of the American Medical Association, vol. 288, no. 4, pp. 455–461, 2002. View at Google Scholar
  59. C. A. Jackevicius, M. Mamdani, and J. V. Tu, “Adherence with statin therapy in elderly patients with and without acute coronary syndromes,” Journal of the American Medical Association, vol. 288, no. 4, pp. 462–467, 2002. View at Google Scholar
  60. J. S. Benner, M. F. Pollack, T. W. Smith, M. F. Bullano, V. J. Willey, and S. A. Williams, “Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy,” American Journal of Health-System Pharmacy, vol. 62, no. 14, pp. 1468–1475, 2005. View at Publisher · View at Google Scholar · View at PubMed
  61. E. S. Parris, D. B. Lawrence, L. A. Mohn, and L. B. Long, “Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 3, pp. 595–599, 2005. View at Publisher · View at Google Scholar
  62. J. S. Schultz, J. C. O'Donnell, K. L. McDonough, R. Sasane, and J. Meyer, “Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population,” American Journal of Managed Care, vol. 11, no. 5, pp. 306–312, 2005. View at Google Scholar